Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved ...

They have already taken the weight-loss sector by storm - now the blockbuster drugs Ozempic and Mounjaro could do the same ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...

Hims & Hers stock plummeted around 30% in early trading Monday after Novo Nordisk announced it was ending a collaboration to ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Hims & Hers stock has fallen nearly 30% on Monday after Novo Nordisk announced it is ending its collaboration with the telehealth company, saying they sell knock-off ...

Novo Nordisk announced it would terminate its Wegovy weight-loss drug agreement with Hims & Hers Health, causing a ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

However, the relationship soured quickly as Novo Nordisk discovered that “Hims & Hers Health, Inc. has failed to adhere to ...